Gene Expression in Samples From Patients With T-Cell Acute Lymphoblastic Leukemia
RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors find better ways to treat cancer.
PURPOSE: This research trial studies gene expression in samples from patients with T-cell acute lymphoblastic leukemia.
Genetic: gene expression analysis
Other: laboratory biomarker analysis
|Study Design:||Observational Model: Case-Only
Time Perspective: Retrospective
|Official Title:||Signaling in Tumorigenesis and Immunity|
- PDLIM2 expression patterns in cancer and control tissues [ Designated as safety issue: No ]
- 8-week survival of human T-cell co-cultured with HTLV-1-transformed T-cell lines [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
tissue, blood, and bodily fluids
|Study Start Date:||January 2012|
|Estimated Primary Completion Date:||March 2100 (Final data collection date for primary outcome measure)|
- To test whether the tumor suppressor candidate gene PDLIM2 is downregulated in human cancers such as T-cell acute lymphoblastic leukemia (T-ALL) and to use the human T-lymphotropic virus 1 (HTLV-1)-mediated in vitro transformation of human T cells as control.
OUTLINE: Previously collected cancer and control tissues are analyzed for the expression patterns of PDLIM2 and other control genes. Human T-cells isolated from human blood are also co-cultured with HTLV-1-transformed T-cell lines.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01520246
|Principal Investigator:||Gutian Xiao, MD||University of Pittsburgh|